Navigation Links
Transcept Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
Date:4/28/2009

RICHMOND, Calif., April 28 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. announced today that Glenn A. Oclassen, President & Chief Executive Officer, is scheduled to present at the Bank of America and Merrill Lynch 2009 Health Care Conference in New York City on Tuesday, May 12, 2009 at 12:40 p.m., Eastern Time.

An audio webcast of the presentation will be available at www.transcept.com. The audio replay of the presentation will be available at the same location through May 26, 2009.

About Transcept Pharmaceuticals (TSPT)

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. On January 30, 2009, Transcept completed a merger with Novacea, Inc. As part of the transaction, Novacea changed its name to "Transcept Pharmaceuticals, Inc." and its NASDAQ ticker symbol to "TSPT." The combined company resources resulting from the merger are expected to enable Transcept to successfully commercialize its lead product candidate, Intermezzo(R). If approved as anticipated, Intermezzo(R) will be the first commercially available sleep aid designed specifically for use in the middle of the night when patients awaken and have difficulty returning to sleep. Intermezzo(R) Phase 3 clinical trials have been completed and, on September 30, 2008, Transcept submitted a New Drug Application (NDA) for Intermezzo(R) to the U.S. Food and Drug Administration (FDA), which was accepted for filing on December 15, 2008. The FDA has assigned a PDUFA date of July 30, 2009 to the Intermezzo(R) NDA.

For further information, please visit the company's website at:

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
2. Transcept Pharmaceuticals Appoints Key Senior Executives
3. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
4. Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)
5. Transcept Pharmaceuticals to Present at 11th Annual BIO CEO & Investor Conference
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 02, 2015 Research and Markets ... "Bioburden Testing Market by Product , Test, Application ... to their offering. The bioburden testing market ... $354.4 Million in 2014, growing at a CAGR of ... of products, the microbial limit testing market is segmented ...
(Date:6/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/2b7734/molecular ) has announced the addition ... Strategy and Forecasts - 2015 to 2019" report ... Market Size, Strategy and Forecasts - 2015 to 2019" ... of pages of information including a complete list of ... help understand test pricing in detail. See ...
(Date:6/2/2015)... -- Meet ARGUS, The World,s First Contactless ... People. Analyze emotions and predict actions. Explore a New ... first Responsive-RPG: "The Eye: Genesis".      (Photo: ... , https://www.youtube.com/watch?v=B1ZEtAZ2Yf8 Imagine ... feelings - and those of others. Being able to ...
(Date:6/2/2015)... 2015 Cirrascale Corporation ®, ... rackmount computing and storage infrastructure for conventional and ... its high density scale-out, two-in-one video delivery and ... . The high density, two-in-one system supports the ... with Intel® Iris™ Pro graphics P6300 and provides ...
Breaking Biology Technology:Bioburden Testing Market 2015 - Global Forecasts to 2019 2Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 2Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 3ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 2ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 3Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 2Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 3
... Conference Call and Webcast Today at 1:00 pm ... FRANCISCO, Calif., June 30 Anesiva,Inc. (Nasdaq: ... its first,commercial product, Zingo(TM) (lidocaine hydrochloride monohydrate) powder,intradermal ... that reduces the pain associated with peripheral,intravenous (IV) ...
... today,received information from Danske Bank, that the Danske Bank ... - through,acquisition today of 502,300 shares now owns 1,804,514 ... to 5,99% of the share capital and 5,99%,of the ... Exiqon,s corporate mission is to combine leading-edge scientific,expertise in ...
... with ADHD ages 6 to 65, RARITAN, N.J., ... and behavioral disorder treated in children(1), and,according to the ... 70 percent of children with ADHD continue to exhibit ... about eight million, or,one in 20, adults in the ...
Cached Biology Technology:Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 2Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 3Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 4Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 5FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults 2FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults 3FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults 4
(Date:5/21/2015)... The Sync Project™ , a global ... today announced a collaborative partnership with Berklee,s Institute ... on collaboration on original research, joint course development and ... collaboration, The Sync Project and BerkleeICE are exploring the ... the 2015-2016 academic year.  The course ...
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... a well-rounded UAS delegation representing private industry, government, and academia, ... AUVSI,s Unmanned 2015 conference last week in Atlanta ... UAS industry met with over 200 hundred people from companies ... ecosystem. "Our message is clear and consistent," ... Rich Knoll . "If you want to fly UAS, you ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... the remote highlands of eastern Suriname discovered 24 species ... with florescent purple markings and other amphibians, fish and ... the findings from a 2005 expedition led by Conservation ... in 2006 demonstrate the value of exploring unknown regions ...
... so many people continue to suffer from life-altering, chronic pain ... answer -- and an effective treatment -- has long eluded ... haven’t worked very well. , A Northwestern University ... to be an old memory trace that essentially gets stuck ...
... cauliflower While orange cauliflower may seem unappealing to ... have identified the genetic mutation behind the unusual hue. ... including maize, potato, rice, sorghum and wheat. , ... Li Li and colleagues -- and described in the ...
Cached Biology News:Researchers find 24 species believed new to science in Suriname rainforest 2Old memory traces in brain may trigger chronic pain 2Old memory traces in brain may trigger chronic pain 3Discovery in orange cauliflower may lead to more nutritious crops 2
... The Partec Cell Counter Analyser counts cells ... the CCA detects only cells, so that ... the results.,While passing through a 250 m ... fluorescence light signal which is used as ...
... Results Laser Capture Microdissection (LCM) enables ... accuracy of molecular assays by starting with ... structures isolated from whole tissue or cytology ... 1996 at the National Institutes of Health ...
Mouse monoclonal antibody raised against a partial recombinant DHX8. NCBI Entrez Gene ID = DHX8...
... antibody raised against a partial ... Immunogen: K6HF (NP_004684, 141 ... recombinant protein with GST tag. ... NM_004693 ...
Biology Products: